NeuBase Therapeutics, Inc. announced the formation of a gene editing advisory board comprised of distinguished leaders of the scientific community who will support the development of the differentiated gene editing capabilities of the Company's PATrOL™ platform. The members of the gene editing advisory board include: George Church, Ph.D. (Chairperson)- Professor Church is a pioneer of genome engineering, DNA sequencing and synthetic biology. He brings significant expertise both in genetics and the biotechnology industry to the NeuBase gene editing advisory board.

He has co-founded 24 biotechnology companies, authored over 500 papers and 140 patent publications. George Church is a professor of genetics and professor of health sciences and technology at Massachusetts Institute of Technology. He is the director of the Center for Genomically Engineered Organs (CGEO) and the Lipper Center for Computational Genetics.

Professor Church is a member of the National Academy of Sciences (2011) and the National Academy of Engineering (2012), and he has received the Franklin Institute's Bower Award for Achievement in Science (2011). He holds a Ph.D. in biochemistry and molecular biology. James Coull, Ph.D.- Dr. Coull has 35 years of experience as a successful entrepreneur and builder of life science companies.

He began his career at Millipore Corporation where he supervised teams of scientists working on the development of new methods and chemistries for synthesis and analysis of DNA, peptides and proteins. He then co-founded and was Vice President R&D at Boston Probes, Inc., where he spearheaded the development of its core PNA technology resulting in probe-based tests to identify pathogenic micro-organisms, genetic mutations and cancers, and which was acquired by Applied Biosystems. Dr. Coull has served as CTO of Ensemble Discovery, CTO and VP Business Development of AdvanDx, and CEO of PNA Innovations. He is currently a scientific and business consultant to various private and public life science companies.

A pioneer of many innovative techniques, Jim is an inventor who is listed on more than 40 issued US patents and has published numerous peer-reviewed scientific articles. He holds a BSc in Chemistry from Colby College (1980) and received his Ph.D. in Biochemistry from Purdue University (1986). Steven Dowdy, Ph.D.- Dr. Dowdy is a cancer biologist, specializing in the development of RNA therapeutics and in understanding cell cycle controls.

He is a professor of cellular and molecular medicine at the University of California San Diego, School of Medicine, where his research focuses on the delivery of RNA therapeutics into cells, including the chemistry of developing endosomal escape technologies. Dr. Dowdy is a past member of the board of directors of the Oligonucleotide Therapeutics Society and consults extensively for biotechnology and pharmaceutical companies. Peter Nielsen, Ph.D.- Dr. Nielsen is a leading expert in gene targeting, RNA interference and chemical replication and translation and was one of the inventors of PNAs in 1991.

He is currently a professor at the University of Copenhagen, where his lab focuses on PNAs in regard to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery, and administration of biopharmaceuticals. He is the co-author of more than 400 scientific papers and reviews, editor of 6 books, inventor on over 20 patents and patent applications, and he serves on the advisory board of four scientific journals, one of which he is section editor. In addition to his esteemed academic career, Dr. Nielsen is the co-founder of two biotechnology companies: PNA Diagnostics A/S, which was acquired by Boehringer Mannheim, and Pantheco A/S, which merged to form Santaris A/S and was subsequently acquired by Roche.

Dr. Nielsen is a member of EMBO and the Danish Academy of Technical Sciences. Dr. Nielsen has been recognized for his seminal contributions to science by earning the Novo Nordic Foundation Prize (1997), the Lundbeck Foundation Prize (1997), and the InstitutCurie Jeanne Loubaresse Prize (Paris/France) (2002). Eriks Rozners, Ph.D.- Dr. Rozners is a leading expert in the chemistry and biochemistry of nucleic acids and brings his expertise to NeuBase as the Company is optimizing and developing its PATrOL™ platform.

He is a professor and the chairman of the Department of Chemistry at Binghamton University, where his lab focuses on the use of organic chemistry to develop unique model systems and tools for the studies and practical applications of nucleic acid biochemistry. Dr. Rozners received a bachelor's degree in chemical engineering and a doctorate in organic chemistry from Riga Technical University. Jeremy Stark, Ph.D.- Jeremy Stark, Ph.D. received his doctorate at the University of Washington/Fred Hutchinson Cancer Research Center working on RNA splicing, and his postdoctoral training was at Memorial Sloan Kettering Cancer Center with Dr. Maria Jasin, where he began his research on chromosomal break repair and gene editing.

He has continued this research focus in his own lab at the City of Hope, where he is now professor of cancer genetics and epigenetics. His research group has developed a series of chromosomal break reporter assays that have been used by several labs around the world. His lab was the first to combine the TREX2 exonuclease with a targeted DSB to cause elevated indel frequencies (Bennardo et al.

2009), leading later to a patent on combining TREX2 and CAS9. Focusing on recent discoveries, his group developed a highly specific assay for canonical non-homologous end joining (C-NHEJ): EJ between two Cas9-induced blunt DSBs without insertion/deletion (indel) mutations (No Indel EJ). This hallmark of C-NHEJ enabled defining key distinctions between this pathway and ALT-EJ, characterizing the function of the C-NHEJ factor XLF (Bhargava et al.

2018), and defining the influence of XLF and DNAPKcs on EJ (Cisneros-Aguirre et al. 2022).